ADARx posts Q3 2026 results after $602.5M IPO and AbbVie placement; onvuzosiran gets FDA Fast Track for HAE
ADARx Pharmaceuticals reported Q3 2026 results on November 12, 2026, with a net loss of $28.1 million and $901.0 million in cash, which it expects to fund operations into 2030. The company closed its Nasdaq IPO and a concurrent AbbVie private placement for about $602.5 million in gross proceeds. In August 2026 the FDA granted Fast Track designation to onvuzosiran for HAE prophylaxis, and the Phase 3 STOP-HAE trial is expected to read out by the end of 2027. Three Phase 2 trials of agazisiran in complement-mediated diseases are ongoing.
Company's press release (SEC filing): ADARx Pharmaceuticals, Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release